CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.
Condition or disease
Radiation: Cyberknife stereotactic body radiation therapy
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
30 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The small HCC patients with decompensated cirrhosis who refused or were ineligible for other treatments.
Primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology
Unfeasible or refusing to undergo other treatments;
Residual normal liver volume ≥700 cc;
With decompensated cirrhosis (Child-Pugh B or C classification);
Without portal vein tumor thrombus;
Eastern Cooperative Oncology Group (ECOG) score 0-1;
Distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm；
Rejecting other therapies such as resection, liver transplantation, etc.
Platelet count≥50 × 109/L, white blood count≥1.5 × 109/L;
Patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.